Semaglutide Cost in the US

Why semaglutide has no single price

If you search for what semaglutide costs, you will get answers ranging from $25 to nearly $1,400 a month, and all of them can be correct at the same time. That is because semaglutide is one molecule sold under several brands, each approved for a different use and each priced on its own track, and because the price you actually pay depends far more on how you buy it than on the drug itself.

Two variables drive almost everything. The first is which brand you are prescribed — Wegovy, Ozempic, Rybelsus, or the newer oral form of Wegovy. The second is the payment route: full retail cash, a manufacturer cash-pay program, a commercial-insurance copay with a savings card, or the narrowed compounded lane. Sort out those two and the number stops being a mystery.

Note: Brand cost numbers move. Manufacturers re-price these programs frequently, and several figures below carry end-dates in 2026. Treat any specific dollar amount here as current to this page’s update date and verify on the manufacturer’s own page before you commit.

What the brands list for

The list price (the sticker, before any discount or insurance) is the ceiling, and very few people actually pay it — but it sets the reference point.

In 2026, Wegovy lists at roughly $1,349 per month’s supply and Ozempic at roughly $1,000-$1,030 per fill. Rybelsus, the original oral diabetes tablet, sits in a similar four-figure retail band. Cash prices at major pharmacies, and discount-card prices through services like GoodRx, shave some off the very top but still land well into the four figures for the injectable pens.

The headline takeaway: nobody who is paying attention pays full retail for brand semaglutide if a cheaper legitimate route is open to them. The rest of this page is those routes.

Manufacturer cash-pay: the NovoCare programs

The single biggest change to brand pricing in the last two years is that Novo Nordisk now sells semaglutide directly to cash-paying patients at a fraction of retail, through its NovoCare Pharmacy channel.

For the Wegovy injection, the direct cash-pay price has been set at around $499 per month for all dose strengths, shipped to your door, for people without insurance or whose plan excludes the drug. A separate, lower savings offer brings new patients to about $199/month for the two starting strengths for the first couple of fills (through mid-2026), stepping up afterward to roughly $349/month for standard pens and $399/month for the high-dose pen. The exact number you see depends on which program you enroll in and when.

This direct-to-patient cash model is the reason brand Wegovy is no longer purely a four-figure drug. It does not require insurance, but it also does not count toward any deductible or out-of-pocket maximum, since you are paying outside your plan by design.

Ozempic has its own NovoCare self-pay pricing, which the Ozempic cost page covers in detail along with the diabetes-coverage picture that makes Ozempic’s economics different.

The new oral pill — the cheapest brand entry

The newest wrinkle, and the cheapest legitimate brand route, is the oral form of Wegovy (oral semaglutide), which became available to self-pay patients in early 2026. Its introductory cash price has been set around $149 per month for the two lowest strengths — by far the lowest sticker any brand semaglutide product has carried.

That price is promotional and dose-dependent: the lowest strengths are the $149 tier, and at least one of those introductory prices is scheduled to step up later in 2026. Rybelsus, the older oral semaglutide tablet for diabetes, is also offered through NovoCare cash-pay at a comparable entry price. For someone who simply wants the lowest-cost legitimate brand semaglutide and does not specifically need an injection, the oral pill has changed the math considerably.

Savings cards and insurance copays

If you have commercial insurance that covers your specific brand for your specific use, a manufacturer savings card can bring a covered fill down to as little as $25 a month, typically with a cap on how much the card saves per fill. These cards are the cheapest route of all when they apply — but they apply narrowly. They exclude anyone on a government plan (Medicare, Medicaid, TRICARE, VA), they generally require an on-label prescription, and they cannot be combined with the cash-pay programs above.

Whether your plan covers semaglutide at all — and what hoops (prior authorization, step therapy, BMI criteria) stand in the way — is a bigger subject than price alone. The GLP-1 insurance coverage page handles that mechanics in full.

Compounded semaglutide: what changed

For a couple of years, the cheapest semaglutide of all came from compounding pharmacies selling through telehealth platforms, often advertised in the $150-$400/month range. That era has largely closed, and it is the single most important correction to make on a 2026 cost page.

Compounding GLP-1s at scale was only broadly legal because semaglutide was on the FDA’s drug shortage list. When the FDA confirmed the injectable shortage was resolved in early 2025, that legal basis went away, with a short wind-down period that has since lapsed. What survives is a narrow, patient-specific 503A lane for documented clinical needs that the FDA-approved product cannot meet — and crucially, cost is not one of those needs. The FDA issued dozens of warning letters to online compounded-GLP-1 sellers in late 2025 and escalated enforcement into 2026.

The practical effect: where compounded semaglutide is still advertised cheaply, supply is tighter, prices have crept up (and often stack consultation, membership, and lab fees on top), and the product is not FDA-approved — its potency, sterility, and contents are not federally verified. A low compounded price in 2026 is not the bargain it was, and it carries legal and safety questions that the brand routes do not. The full legal picture lives on the compounded GLP-1 legal status page.

Direct-to-consumer channels

A newer entrant is government- and manufacturer-aligned direct-to-consumer pricing, including the TrumpRx channel that launched in early 2026, advertising brand semaglutide tablets and injections at reduced flat monthly rates (broadly in the low-to-mid hundreds). These are positioned as access to the FDA-approved products at lower cash prices, distinct from compounded knock-offs. Pricing and availability here are moving quickly and the advertised figures are not always independently verified, so the TrumpRx & DTC GLP-1 pricing page tracks this separately rather than freezing a number on this page.

Medicare, Medicaid, and negotiated prices

Public coverage is its own maze. By statute, Medicare does not cover any semaglutide product purely for weight loss, though it covers Ozempic and Rybelsus for diabetes and Wegovy for its approved cardiovascular-risk indication. Medicaid coverage for obesity is optional and varies by state, with only around a dozen states covering GLP-1s for weight loss as of early 2026.

Looking ahead, the three semaglutide products are near the top of the next round of Medicare price negotiations under the Inflation Reduction Act, with negotiated prices set to take effect in 2027, not 2026. That will lower the price for Medicare beneficiaries on the relevant indications, but it does not change cash or commercial pricing today.

Is there a generic?

No. Semaglutide is under patent protection in the US expected to run into the early 2030s, so there is no FDA-approved generic. Anything marketed as cheap generic semaglutide is, in practice, either a compounded product (see above) or a gray-market research vial — neither of which is an FDA-approved generic, and the latter is not a legitimate patient route at all. The genuinely cheap legitimate options in 2026 are the manufacturer cash-pay programs, the oral pill, and a covered insurance copay — not a generic.

So what will you actually pay?

Walk it back to those two variables. If you have commercial insurance that covers your brand for your use, target the $25-ish savings-card copay and treat coverage hoops as the real work. If you are paying cash and want the lowest legitimate brand price, the oral pill near $149 is the current floor, with the injection cash-pay programs at $349-$499 if you need a pen. If you are on Medicare or Medicaid, your answer depends entirely on indication and state, and weight-loss-only use is mostly excluded for now. And if a telehealth ad is quoting you a very low compounded number, understand that you are looking at a narrowed, non-FDA-approved lane, not the bargain it once was.

For the brand-specific deep dives, see the Ozempic cost page and the Wegovy cost page; for how to actually obtain a prescription across these routes, see how to get semaglutide.

This page is educational and current as of its update date. It is not medical, legal, or financial advice, and pricing programs change frequently. Confirm any figure with the manufacturer, pharmacy, or your insurer before relying on it.